Skip to main content
SpringerLink
Log in

Checkpoint inhibitors in head and neck cancer

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Head and neck cancer (HNC) are aggressive cancers and represents the sixth leading cancer by incidence worldwide. This kind of cancer constitutes about 3% of all newly diagnosed malignant tumors in humans, and this percentage is likely to increase in the future. Most common available treatment methods which include surgery, radiotherapy, and chemotherapy are associated with low survival outcomes in combination with substantial toxicities emphasize the necessity for novel treatment strategies.The combination immunotherapies represent a fundamental step in the progress towards improving responses, and immune checkpoint inhibitors will likely become the immunotherapeutic backbone of future cancer treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Guidi A, Codecà C, Ferrar D. Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. Med Oncol. 2018;35(3):37.

    Article  Google Scholar 

  2. Cavalieri S, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. Cancer Treat Rev. 2018;65:78–86.

    Article  Google Scholar 

  3. Fuereder T. Immunotherapy for head and neck squamous cell carcinoma. Memo. 2016;9:66–9.

    Article  Google Scholar 

  4. Ferris RL, Blumenschein G Jr., Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.

    Article  Google Scholar 

  5. Dorsey K, Agulnik M. Promising new molecular targeted therapies in head and neck cancer. Drugs. 2013;73(4):315–25.

    Article  CAS  Google Scholar 

  6. Pai SI, Zandberg DP, Strome SE. The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. Oral Oncol. 2016;61:152–8.

    Article  CAS  Google Scholar 

  7. Pai SI. Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. Oncoimmunology. 2013;2(5):e24065.

    Article  Google Scholar 

  8. Moskovitz J, Moy J, Ferris RL. Immunotherapy for Head and Neck Squamous Cell Carcinoma. Curr Oncol Rep. 2018;20:22. https://doi.org/10.1007/s11912-018-0654-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Chow LQM, Haddad R, Gupta S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34(32):3838–45.

    Article  CAS  Google Scholar 

  10. Bauml J, Seiwert TY, Gilbert J, Pfister DG, Worden F, Liu SV, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 2017;35:1542–9.

    Article  CAS  Google Scholar 

  11. Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156–67. Jan.

    Article  CAS  Google Scholar 

  12. Cohen, ESMO 2017; September, 11; Madrid, Spain, Oral Presentation. 2017

  13. Siu LL, Even C, Mesía R, et al. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol. 2018;5(2):195–203. https://doi.org/10.1001/jamaoncol.2018.4628

    Article  Google Scholar 

  14. Licitra LF, Haddad RI, Even C, et al. EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol. 2019;37(15):6012–6012.

    Article  Google Scholar 

  15. Galluzzi L, Zitvogel L, Kroemer G. Immunological mechanisms underneath the efficacy of cancer therapy. Cancer Immunol Res. 2016;4:895–902.

    Article  CAS  Google Scholar 

  16. Burtness B, Harrington KJ, Greil R, et al. KEYNOTE-048: Fase III study of first line pembroluzimab (P) for recurrent/metastasic head and neck squamous cell carcinoma (R/M HNSCC). ASCO. 2019;The ASCO Post

  17. Teng F, Kong L, Meng X, Yang J, Yu J. Radiotherapy combined with immune checkpoint blockade immunotherapy: achievements and challenges. Cancer Lett. 2015;365:23–9.

    Article  CAS  Google Scholar 

  18. Kalbasi A, June CH, Haas N, Vapiwala N. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123:2756–63.

    Article  CAS  Google Scholar 

  19. Park B, Yee C, Lee KM. The effect of radiation on the immune response to cancers. Int J Mol Sci. 2014;15:927–43.

    Article  Google Scholar 

  20. Ferris RL, et al. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2018;63:48–60. https://doi.org/10.1016/j.ctrv.2017.11.008

    Article  CAS  PubMed  Google Scholar 

  21. Sacco AG, Chen R, Ghosh D, et al. An open label, nonrandomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of cohort 1 interim analysis. J Clin Oncol. 2019;37(suppl):Abstr 6033

    Article  Google Scholar 

  22. Adkins D, et al. Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study. Lancet Oncol. 2018;19:1082–93.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiology Department, Finis Terrae University School of Dentistry, Santiago, Chile

    Ilson Sepulveda

  2. Oncology Service, General Hospital of Concepción, Concepción, Chile

    Rodrigo Ascui

  3. Radiology Department, Division of Neuroradiology, University of Michigan Health System, Ann Arbor, MI, USA

    A. Andrés Capizzano

  4. ENT-Head and Neck Surgery Service, General Hospital of Concepcion, San Martin Av. 1436, Concepcion, Chile

    Ilson Sepulveda

Authors
  1. Ilson Sepulveda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rodrigo Ascui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Andrés Capizzano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ilson Sepulveda.

Ethics declarations

Conflict of interest

I. Sepulveda, R. Ascui, and A. A. Capizzano declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sepulveda, I., Ascui, R. & Capizzano, A.A. Checkpoint inhibitors in head and neck cancer. memo 12, 249–252 (2019). https://doi.org/10.1007/s12254-019-0511-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-019-0511-8

Keywords

Search

Navigation